Business Wire

CORRECTING and REPLACING MultiBank Group Continues Its Global Expansion by Obtaining a Regulatory License in the Dubai International Financial Centre (DIFC)

Share

Fourth paragraph, first sentence of release dated October 11, 2020, should read: The MultiBank Group is now one of the largest financial derivatives groups in the world with an annual turnover of over US$ 1.9 Trillion... (instead of The MultiBank Group is now one of the largest financial derivatives groups in the world with a daily turnover of over US$ 1.9 Trillion...). Additionally, the multimedia has been updated to reflect new images.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201011005065/en/

MultiBank Group continues its global expansion by obtaining the DFSA regulatory license in the DIFC. (Graphic: Business Wire)

MultiBank Group continues its global expansion by obtaining the DFSA regulatory license in the DIFC. (Graphic: Business Wire)

The updated release reads:

MULTIBANK GROUP CONTINUES ITS GLOBAL EXPANSION BY OBTAINING A REGULATORY LICENSE IN THE DUBAI INTERNATIONAL FINANCIAL CENTRE (DIFC)

MultiBank Group, one of the largest online financial derivatives providers worldwide, represented by its subsidiary, MEX Australia Pty Ltd, has secured a reputable and strategic commercial license from the Dubai Financial Services Authority (DFSA).

The addition of this coveted license extends the group’s regulatory arsenal to include heavily regulated companies regulated by ASIC in Australia, BaFin in Germany, FMA in Austria, CNMV in Spain, FSC in the British Virgin Islands and CIMA in the Cayman Islands.

With the opening of the new office in the DIFC, the MultiBank Group now operates through 21 offices in 5 continents.

The MultiBank Group is now one of the largest financial derivatives groups in the world with an annual turnover of over US$ 1.9 Trillion and Gross Profit of US$85.6 million in 2019, facilitating over 90,000 trades per day and services over 280,000 customers worldwide.

Naser Taher, Chairman of MultiBank Group, said:

“The DFSA license marks yet another momentous occasion for MultiBank Group and is a testament to the strength of our group and commitment to the MENA region. The DFSA approval underscores our dedication to continue to provide our retail and institutional clients with world class services and the highest level of security of funds”.

Courtney Fitzsimmons, CEO of MEX Australia Pty Ltd, added:

We have thoroughly enjoyed working with the DFSA throughout this process and proudly take a position here in the DIFC. In this evolving market we are thrilled to add to our regulatory arsenal, and look forward to making our mark in Dubai

For more information about the MultiBank Group, please visit www.multibankfx.com.

For more information about MEX Australia Pty Ltd (DIFC Branch), please visit www.mexexchange.ae

About MultiBank Group:

MultiBank Group was established in California, USA in 2005. It boasts a daily trading volume of over US $7.2 billion and services an extensive client base of over 280,000 customers across 90 countries. Since its launch, MultiBank Group has evolved into one of the largest online financial derivatives providers worldwide. The group offers a combination of the most advanced and award-winning trading platforms, up to a 500:1 leverage on CFD trading with products including Shares, Commodities, Indices, Digital Assets, Metals and Foreign Exchange (Forex).

Contact information

Media Enquiries:
Ruby Korver | Communications Officer
MultiBank Group
Email: ruby.korver@multibankfx.com
Phone: +971 487 513 50

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook1.12.2020 07:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a specialty-care focused biopharmaceutical group, today will host a virtual Capital Markets Day to highlight the Group’s new strategic priorities with the aim of driving continued growth and bringing transformative medicines to patients. David Loew, Chief Executive Officer of Ipsen stated: “Our new Group strategy positions Ipsen for long-term success by focusing together for patients and society. We will reinforce our commitment to Oncology, Rare Disease and Neuroscience by strengthening and accelerating our external innovation efforts and pipeline in clearly-defined segments. Through prioritization and collaboration, we will drive efficiencies to support investment in our pipeline. We are building on a strong foundation of engaged employees, agile development capabilities and global commercial footprint. I am energized to execute on our key strategic priorities to create long-term value for all stakeholders.” Bring the full potential

Process Sensing Technologies, a Battery Ventures Company, Announces New Majority Investment from AEA Investors1.12.2020 06:01:00 CETPress release

Process Sensing Technologies (“PST”), a global manufacturer of instruments, analyzers and sensors for precision measurement and monitoring in a variety of critical industries, announced that global private-equity firm AEA Investors LP (“AEA”) has made a majority investment in the company. PST backer Battery Ventures will maintain a minority stake in the business. Baird acted as exclusive sell-side advisor; other terms of the transaction were not disclosed. PST—a platform constructed under Battery’s ownership comprising seven global businesses—sells its sensors and other technologies into industries including pharmaceuticals, life sciences, specialty gases, petrochemicals, food-and-beverage, semiconductors and building automation. The company’s products measure moisture, oxygen and pressure, among other things, and help improve customers’ profitability while helping them stay compliant with often-stringent industry regulations. Battery began the PST platform journey with its acquisition

Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited1.12.2020 00:00:00 CETPress release

Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (“Takeda”) in Asia Pacific, igniting efforts to strengthen its R&D capability in the global small molecule pharmaceuticals business. In June, the firms announced an agreement under which Celltrion would acquire 18 "Primary Care" product assets in the Asia Pacific area for a total of USD 278 million inclusive of milestone payments from Takeda. Celltrion proceeded with the acquisition process through its newly established subsidiary in Singapore, "Celltrion Asia Pacific Pte, Ltd."1 ("Celltrion APAC"). Upon completion of the acquisition, Celltrion APAC will assume the ownership of the rights to patents, trademarks, and sales of 18 products sold in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia. The 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Eda

Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific1.12.2020 00:00:00 CETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) for a total value of $278 million USD inclusive of milestone payments. The portfolio includes 18 pharmaceutical products and over-the-counter (OTC) products sold in Asia Pacific, which is part of Takeda’s Growth & Emerging Markets Business Unit. This divestment agreement was first announced in June 2020. The divested portfolio includes pharmaceutical products and OTC products in the Cardiovascular, Diabetes and General Medicine therapeutic areas, sold in Australia, Hong Kong, Macau, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand. The products, while addressing key patient needs in these countries and territories, are outside of the business areas Takeda has chosen as core to its global long-term growth. As part of the deal, Takeda will continue to manufacture the portfol

Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE ® ) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)30.11.2020 22:58:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE®) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need. ONIVYDE® is currently approved in the United States and in Europe in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. ONIVYDE® is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. An ongoing Phase III randomized study (RESILIENT; NCT03088813) trial is being conducted to assess the efficacy and safety of investigational irinotecan liposome injection (ONIVYDE®) as a monotherapy for SCLC study patients who have progressed on or a

Amblin Partners Announces New Multi-Year Film Distribution Partnership With Universal Filmed Entertainment Group30.11.2020 22:00:00 CETPress release

Amblin Partners today announced a new multi-year film distribution partnership with Universal Filmed Entertainment Group, as well as a series of new agreements that chart a clear course for the next phase of growth for one of the world’s leading independent film and television studios. The new deals were announced this morning by Steven Spielberg, Amblin’s Founder and Chairman. Remarked Spielberg: “My decades-long relationship with Universal truly transcends any single business deal, and to once again renew our corporate vows reaffirms that Universal is Amblin’s home. In addition to Universal, we are blessed to continue forward with a global family of partners, including Alibaba, eOne and Reliance, each of which has supported us for many years and enabled our storytelling to touch the lives of millions of moviegoers around the world. I would also like to extend my deepest gratitude to my dear friends Jeff Skoll and David Linde for an incredible run as formal partners; and my congratula